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Abstract
Introduction: Prospective studies investigating flavonoid intake and dementia risk are
scarce. The aims of this study were to examine associations between flavonoid intake
and the risk of incident dementia and to investigate whether this association differs in
the presence of lifestyle risk factors for dementia.
Methods:Weexamined associations in 55,985 participants of theDanishDiet, Cancer,
and Health Study followed for 23 years. The Phenol-Explorer database was used to
estimate flavonoid intakes. Information on incident dementia and dementia subtypes
was obtained using Danish patient and prescription registries. Hazard ratios (HRs)
were calculated using restricted cubic splines in multivariable-adjusted Cox propor-
tional hazards models.
Results: For incident dementia, moderate compared to low intakes of flavonols (HR:
0.90 [0.82, 0.99]), flavanol oligo+polymers (HR: 0.87 [0.79, 0.96]), anthocyanins (HR:
0.84 [0.76, 0.93]), flavanones (HR: 0.89 [0.80, 0.99]), and flavones (HR: 0.85 [0.77,
0.95]) were associated with a lower risk. For vascular dementia, moderate intakes of
flavonols (HR: 0.69 [0.53, 0.89]) and flavanol oligo + polymers (HR: 0.65 [0.51, 0.83])
were associated with lower risk. Flavonoid intakes were not significantly associated
with Alzheimer’s disease or unspecified dementia. The inverse association between
total flavonoid intake and incident dementia was stronger in “ever” smokers than in
“never” smokers and in thosewithout hypercholesterolemia versus thosewith hyperc-
holesteremia. Furthermore, the inverse associationof vascular dementiawith amoder-
ate total flavonoid intakewas stronger in “ever” smokers and thosewhowere “normal”
to “overweight” versus “never” smokers or those whowere “obese,” respectively.
Conclusion: A moderate intake of flavonoid-rich foods may help to reduce dementia
risk.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
© 2021 The Authors. Alzheimer’s & Dementia: Translational Research & Clinical Interventions published byWiley Periodicals, Inc. on behalf of Alzheimer’s Association.
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1 INTRODUCTION
The number of dementia cases (>50 million worldwide) is predicted
to reach 152 million by 2050.1 With coordinated action to address
known risk factors, the 2020 Lancet Commission on Dementia esti-
mated that up to 40% of these cases could be prevented.2 Prevention
is now recognized as an important strategy particularly given the lim-
ited efficacy of pharmacological treatment approaches. The first line of
defense proposed against the development and progression of demen-
tia is lifestyle-related factors. Dietary components, particularly those
that influence vascular risk factors, could be important.3
Cardiovascular risk factors such as smoking, diabetes, and hyper-
tension are strongly associated with a higher risk of cognitive
impairment and dementia.4 Guidelines recommend targeting midlife
cardiovascular risk factors for prevention of dementia.5,6 The signifi-
cantly lower risk of cardiovascular disease (CVD) observedwith higher
dietary flavonoid intake7,8 could therefore be important in dementia
prevention. Flavonoids, a class of polyphenolic compounds found
in abundance in plant-derived foods and beverages such as fruits,
vegetables, dark chocolate, tea, and red wine, have consistently been
associatedwith cardiovascular health.9 There is also a growing body of
evidence for cognitive benefits.10 Previous studies have observed that
total flavonoid intake is associated with lower cognitive decline11,12
and improved executive function in adults with mild to moderate
Alzheimer’s disease (AD)13 (the most common form of dementia). A
protective effect of high flavonoid intake on CVD risk, its associated
risk factors, and cognitive function provides a strong rationale to inves-
tigate the relationship between flavonoid intake and incident demen-
tia. No firm conclusions can be drawn from the few prospective studies
to date that have investigated flavonoid intake and dementia.14–17
Flavonoids are categorized into six main subclasses based on
their chemical structure: flavonols, flavanols, flavanones, flavones,
anthocyanins, and isoflavones.9 As structural variations between
the flavonoid subclasses and respective major compounds influence
bioavailability and biological activity it is informative to investigate the
relationships between particular flavonoid subclasses and dementia,18
particularly for those flavonoid subclasses including flavanols, antho-
cyanins, and flavanones, for which there is evidence in the literature
for a neuro-protective effect.10 Furthermore, there is evidence that
the association between flavonoid intake and CVDmay bemodified by
risk factors for CVD including smoking and alcohol intake;7,19 whether
the same holds true for flavonoids and dementia warrants further
investigation.
Thus, the primary aims of this studywere to investigate associations
between incident dementia and intakes of (1) total flavonoids, (2)
flavonoid subclasses, and (3) flavonoid compounds (where significant
associations were observed for a particular subclass), in the Danish
Diet, Cancer, and Health cohort. Secondary aims were to investigate
whether these associations differed according to the presence of
known risk factors for both CVD and dementia, that is, diabetes,
hypertension, obesity, high cholesterol, alcohol, and smoking.
2 METHODS
2.1 Study population
From December 1993 through May 1997, 160,725 men and women
from the greater areas of Copenhagen and Aarhus were invited to
participate in the Danish Diet, Cancer, and Health Study. The study
recruited 57,053 participants between the ages of 50 and 65 years
who had no previous cancer diagnosis. Of these, 56,468 completed
a food frequency questionnaire (FFQ). All Danish residents living in
Denmark since 1968 are assigned a civil registry number, a unique
and permanent 10-digit number allowing cross-linking of participants
to nationwide registers such as the Civil Registration System, the
IntegratedDatabase for LabourMarket Research, the Danish National
Prescription Registry, and the Danish National Patient Register
(DNPR). The DNPR holds information on all patients discharged from
non-psychiatric hospitals since 1977 as well as all patient contact with
psychiatric inpatient, emergency department, and outpatient specialty
clinics since 1995.20 This information includes one primary diagnosis
and one or more secondary diagnoses defined by the International
Classification of Diseases (ICD): the 8th revision (ICD-8) until 1993
and the 10th revision (ICD-10) from 1994.21 The Danish prescription
registry holds information on all filled prescriptions from Danish
pharmacies since 1994. Each drug is classified by the anatomical
therapeutic chemical (ATC) code.22 In the present study, participants
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were excluded if they had implausible energy intakes (<2092 kJ/d
[<500 kcal/d] and >20,920 kJ/d [>5000 kcal/d]; n = 205); if they had
missing covariates or were extreme outliers (n= 214); or if they at the
time of recruitment had a diagnosis of dementia (n = 64). A dementia
diagnosis consisted of a prior diagnosis of AD (ICD-8: 29009 and
29010, ICD-10: F00 and G30), vascular dementia (ICD-8: 29309 and
29319, ICD-10: F01), or unspecified dementia (ICD-8: 29011, 29018,
and 29019, ICD-10: F02 and F03.9); see Figure S1 in supporting
information.
This studywas approved by theDanishData ProtectionAgency (Ref
no 2012-58-0004 I-Suite nr: 6357, VD-2018-117).
2.2 Exposures
For this study the exposures of interest were intakes of total
flavonoids; flavonoid subclasses; and, if relevant, the individual
flavonoid compounds within the respective subclass, only where mean
intakes of the subclasses were >5 mg/d. Calculations of flavonoid
intake in this cohort have been described previously.7 Briefly, esti-
mates of the flavonoid content of all foods and beverages in the FFQ
were obtained from the Phenol-Explorer database.23 All 219 flavonoid
compounds were grouped into 10 subclasses based on their chemical
structure (flavonols, flavanol monomers, flavanol oligo+ polymers, fla-
vanones, flavones, anthocyanins, isoflavones, dihydrochalcones, dihy-
droflavonols, and chalcones). Data used here are those derived from
analyses by normal phase chromatography.24 Total flavonoid intake
was calculated by summing each of the 219 flavonoid compounds.
The content of flavonoids was expressed as aglycone equivalents in
mg/100 g food fresh weight.24
2.3 Study outcomes
Our primary outcome, incident dementia, was defined as a dementia-
related health-care visit or a prescription for an anti-dementia drug.25
About two thirds of all dementia cases are diagnosed in the secondary
care setting and are recorded in the DNPR.26 Dementia health-care
visits were defined as a hospitalization or an outpatient visit with a
primary or secondary diagnosis code for AD (ICD-10: F00, G30), vas-
cular dementia (ICD-10: F01), or unspecified dementia (ICD-10: F02
and F03.9) recorded in the DNPR. These diagnoses, for total demen-
tia, have a positive predictive value (PPV) of 85.8% in the DNPR.27 To
capture those treated in the primary sector, we included information
on claimed prescriptions for anti-dementia drugs (ATC code: N06D).
Secondary outcomes were hospitalization or outpatient visit for each
dementia subtype discretely.
2.4 Covariates
At study enrolment, data on age, sex, duration of education (≤7
years, 8–10 years, ≥11 years), smoking habits, alcohol intake, daily
RESEARCH INCONTEXT
1. Systematic review: Thebeneficial effect of a higher habit-
ual flavonoid intake on cardiovascular disease risk, its risk
factors, and cognitive function provides a strong rationale
to investigate the relationship between the range of dif-
ferent flavonoids present in the habitual diet and demen-
tia. Few prospective studies have investigated flavonoid
intake and dementia, with conflicting results reported.
2. Interpretation: Our findings suggest that a higher habit-
ual intake of specific flavonoid subclasses, particularly the
flavonols and flavanol oligo + polymers, was associated
with a lower risk of incident, particularly vascular, demen-
tia. The associationswere non-linear; moderate flavonoid
intakes, within readily achievable daily dietary intakes,
were associated with a lower risk of dementia.
3. Future directions: The current findings require repli-
cation in other populations to confirm the association
between intakes of different flavonoids and dementia.
Clinical trials and mechanistic studies to investigate the
role of specific flavonoid subclasses on long-term cogni-
tive health are also warranted.
activity, and diet were collected by self-administered questionnaires.
Anthropometry, including height and weight, and blood pressure were
measured and a blood sample taken for determination of serumcholes-
terol levels. Average annual income (defined as household income after
taxation and interest, for the value of the Danish currency in 2015)
over 5 years was used as a representation of socioeconomic status.
ICD-8 and ICD-10 codes were used to determine prevalent chronic
kidney disease, ischemic heart disease, ischemic stroke, peripheral
artery disease, heart failure, atrial fibrillation, and cancers. For treat-
ment of diabetes mellitus, both self-reported data and data on filled
prescriptions for insulin and non-insulin medication were used. Pres-
ence of hypertension was defined as at least one of (1) systolic blood
pressure≥140mmHg, (2) self-reported hypertension, (3) self-reported
use of blood pressure-lowering medication. Hypercholesterolemia
was defined as at least one of (1) non-fasting serum cholesterol
≥6.2mmol/L, (2) self-reported hypercholesterolemia, (3) self-reported
statin use.
2.5 Statistical analysis
Participants’ follow-up timewas based on the date of study enrollment
to, whichever came first, prescription of dementiamedication, the date
of dementia health-care visit, death, emigration, or end of follow-up
(August 2017).
Cox proportional hazards models with restricted cubic splines were
used to investigate relationships between flavonoid intake and the
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primary and secondary outcomes. Using restricted cubic splines, we
allowed the association to be non-linear. All hazard ratios (HRs) and
95% confidence intervals (CIs) were obtained from the model with
the exposure fitted as a continuous variable; HR estimates were
reported for the median intake in each quintile with the first quin-
tile median as the reference point, representing the lowest flavonoid
intake, and were graphed over a fine grid of x values. For visual sim-
plicity, the graphs of HRs derived from the fitting of cubic splines had
x-axis values restricted to intakes within three standard deviations
of the mean for each exposure. Throughout, cause-specific hazards
models were used censoring individuals at death, rather than treat-
ing death as a competing risk.28 Cox proportional hazards assump-
tions were tested using log-log plots of the survival function versus
time and assessed for parallel appearance. Potential confounders of
flavonoid intake and dementia were chosen a priori as covariates.
Three models of adjustment were used: (1a) minimally adjusted: age
and sex; (1b) multivariable-adjusted: age, sex, body mass index [BMI],
smoking status (current/former/never), physical activity (total daily
metabolic equivalent), pure alcohol intake (g/d), duration of education,
and socioeconomic status (income); (2) multivariable-adjusted: energy
and potential dietary confounders; covariates in model 1b plus energy,
intakes (g/d) of fish, red meat, processed meat, polyunsaturated fatty
acids, monounsaturated fatty acids, and saturated fatty acids.
To examine possible effect modification, additional analy-
ses were stratified by known dementia risk factors, namely:
diabetes (present/absent), hypertension (present/absent), BMI
(above/below 30 kg/m2), hypercholesterolemia (present/absent), alco-
hol (above/below 20 g/d), and smoking (ever/never). When stratifying
by alcohol intake we excluded all participants with an alcohol intake
of zero (n = 1293), due to potential underlying pathologies or habits
such as medication use in which alcohol intake is contraindicated (for
example anxiolytics, antidepressants, and hypnotics). As there is the
potential for residual confounding, when stratifying by smoking status,
alcohol intake, and BMI, the corresponding continuous variables were
included in the model where appropriate (smoking pack-years, alcohol
intake, andBMI, respectively). To examine the robustness of the associ-
ations, we conducted a sensitivity analysis using only dementia-related
health-care visits as the outcome. All analyses were undertaken using
STATA/IC 14.2 (StataCorp LLC) and R statistics (R Core Team, 2019).29
Statistical significance was set at P≤ 0.05 (two-tailed) for all tests.
3 RESULTS
This population of 55,985Danish citizens, with amedian (interquartile
range [IQR]) age of 56 (52–60) years at study entry, had amedian (IQR)
follow-upof 21 (20–22) years. During amaximumof 23 years of follow-
up (1,073,280 person-years), 2955 individuals received a diagnosis of
dementia, 1348participants had a health-care visit for AD, 329 for vas-
cular dementia, and 1338 for unspecified dementia, with some partici-
pants receiving a diagnosis of two ormore types of dementia.
3.1 Baseline characteristics
The median (IQR) total flavonoid intake was 494 (286–804) mg/d. The
median (IQR) intakes for the flavonoid subclasses are presented in
Table 1. Thebaseline characteristics of the studypopulationoverall and
by quintiles of total flavonoid intake are shown in Table 2. Compared
to participants in the lowest quintile of total flavonoid intake, those
in higher quintiles were more likely to be female, have a lower BMI,
be more physically active, have never smoked, have a higher degree of
education, andhave a higher income. Those in the higher quintileswere
also less likely to be hypertensive or hypercholesteremic, and tended
to have a lower prevalence of diabetes and CVD, which in themselves
are risk factors for dementia. Furthermore, participants in the higher
quintiles consumedmore fish; ate less red and processed meat; and, as
expected, ate more fruits and vegetables.
3.2 Associations between total flavonoid intake
and incident dementia and dementia subtypes
The non-linear inverse association between total flavonoid intake and
incident dementia (Figure 1) did not reach statistical significance at
any level of flavonoid intake (Table 3). However, after adjusting for
TABLE 1 Flavonoid subclasses, natural sources, and intake per day
Flavonoid subclass Natural sources23 Intake (mg/d)a
Flavonols Tea (black), fruit (berries and pome), cocoa, and onions 38 [23–73]
Flavanol monomers Tea (black and green), wine, cocoa, chocolate, fruit
(pome, drupe, tropical, and berries), nuts, and beans
66 [25–268]
Flavanol oligo+polymers Tea (black and green), wine, cocoa, fruit (pome, drupe,
tropical, and berries), and beans
255 [157–395]
Flavones Olive oil, olives, herbs, andwhole grain wheat 5 [3–8]
Flavanones Citrus fruit and herbs 17 [8–38]
Anthocyanins Pomegranate, berries, and redwine 20 [11–50]
Isoflavones Soybeans, soy foods, and beans <1
aMedian [interquartile range].
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TABLE 2 Baseline characteristics of study population
Total population













494 [286–804] 173 [127–212] 320 [286–356] 494 [441–548] 726 [659–804] 1201 [1024–1435]
Sex n (%male) 26,626 (47.6) 6469 (57.8) 5733 (51.2) 5329 (47.6) 4988 (44.5) 4107 (36.7)
Age (y) 56 [52–60] 56 [52–60] 56 [52–60] 56 [52–60] 56 [52–60] 55 [52–59]
BMI (kg/m2) 25.5 [23.3–28.2] 26.1 [23.8–28.9] 25.9 [23.6–28.5] 25.6 [23.3–28.3] 25.3 [23.2–27.9] 24.9 [22.7–27.4]
MET score 56.5 [37.0–84.8] 51.0 [32.0–78.0] 55.5 [36.3–84.0] 57.5 [38.3–85.0] 58.3 [38.5–87.0] 60.0 [39.5–88.5]
Smoking status, n (%)
Never 19,648 (35.1) 2716 (24.3) 3743 (33.4) 3991 (35.6) 4458 (39.8) 4740 (42.3)
Former 16,134 (28.8) 2692 (24.0) 3026 (27.0) 3264 (29.2) 3594 (32.1) 3558 (31.8)
Current 20,203 (36.1) 5789 (51.7) 4428 (39.5) 3942 (35.2) 3145 (28.1) 2899 (25.9)
Education, n (%)
≤7 y 18,438 (32.9) 5120 (45.7) 4263 (38.1) 3603 (32.2) 3024 (27.0) 2428 (21.7)
8–10 y 25,789 (46.1) 4887 (43.6) 5257 (47.0) 5335 (47.6) 5315 (47.5) 4995 (44.6)
≥11 y 11,730 (21.0) 1184 (10.6) 1673 (14.9) 2255 (20.1) 2851 (25.5) 3767 (33.6)
Mean household income, n (%)
≤3,94,700DKK/y 13,886 (24.8) 3342 (29.8) 2744 (24.5) 2709 (24.2) 2574 (23.0) 2517 (22.5)
3,94,701–5,70,930
DKK/y
14,000 (25.0) 3268 (29.2) 2998 (26.8) 2714 (24.2) 2601 (23.2) 2419 (21.6)
5,70,931–7,58,297
DKK/y
14,049 (25.1) 2915 (26.0) 3032 (27.1) 2900 (25.9) 2620 (23.4) 2582 (23.1)
>7,58,297DKK/y 14,050 (25.1) 1672 (14.9) 2423 (21.6) 2874 (25.7) 3402 (30.4) 3679 (32.9)
Hypertensive 24,913 (44.5) 5355 (47.8) 5098 (45.5) 5047 (45.1) 4838 (43.2) 4575 (40.9)
Hypercholesterolemic 28,590 (51.1) 6052 (54.1) 5784 (51.7) 5830 (52.1) 5617 (50.2) 5307 (47.4)
Comorbidities, n (%)
Diabetes 1177 (2.1) 279 (2.5) 219 (2.0) 253 (2.3) 215 (1.9) 211 (1.9)
Heart failure 220 (0.4) 56 (0.5) 54 (0.5) 39 (0.3) 40 (0.4) 31 (0.3)
Ischemic stroke 778 (1.4) 218 (1.9) 151 (1.3) 145 (1.3) 130 (1.2) 134 (1.2)
Ischemic heart
disease
2192 (3.9) 586 (5.2) 422 (3.8) 435 (3.9) 396 (3.5) 353 (3.2)
Peripheral artery
disease
498 (0.9) 171 (1.5) 114 (1.0) 84 (0.8) 61 (0.5) 68 (0.6)
Atrial fibrillation 277 (0.5) 57 (0.5) 55 (0.5) 59 (0.5) 49 (0.4) 57 (0.5)
CKD 202 (0.4) 43 (0.4) 33 (0.3) 44 (0.4) 41 (0.4) 41 (0.4)
Cancer 246 (0.4) 55 (0.5) 42 (0.4) 60 (0.5) 33 (0.3) 56 (0.5)
Medication use, n (%)
Insulin treated 380 (0.7) 78 (0.7) 65 (0.6) 86 (0.8) 80 (0.7) 71 (0.6)
Antihypertensive 6893 (12.3) 1360 (12.1) 1421 (12.7) 1405 (12.5) 1360 (12.1) 1347 (12.0)
Statin 1073 (1.9) 262 (2.3) 210 (1.9) 221 (2.0) 212 (1.9) 168 (1.5)
HRT
Never 15,965 (28.5) 2605 (23.3) 3047 (27.2) 3268 (29.2) 3268 (29.2) 3777 (33.7)
Current 8816 (15.7) 1293 (11.5) 1569 (14.0) 1698 (15.2) 2001 (17.9) 2255 (20.1)
Former 4547 (8.1) 821 (7.3) 844 (7.5) 895 (8.0) 934 (8.3) 1053 (9.4)
(Continues)
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TABLE 2 (Continued)
Total population











NSAID 18,138 (32.6) 3538 (31.8) 3528 (31.7) 3636 (32.7) 3636 (32.6) 3800 (34.2)
















38 [25–55] 33 [22–49] 38 [25–54] 34 [27–57] 41 [28–59] 40 [27–57]
Redmeat intake
(g/d)
78 [57–107] 80 [58–108] 81 [59–110] 80 [58–110] 78 [57–107] 72 [52–99]
Processedmeat
intake (g/d)
25 [14–40] 28 [17–45] 26 [16–42] 25 [14–40] 23 [14–38] 20 [11–34]
Dietary fiber intake
(g/d)
20 [16–25] 16 [13–20] 19 [16–23] 21 [17–25] 22 [18–27] 23 [19–29]
Saturated FA (g/d) 31 [24–39] 29 [23–37] 31 [24–39] 32 [24–40] 32 [25–41] 32 [24–41]
Polyunsaturated FA
(g/d)
13 [10–17] 12 [9–16] 13 [10–17] 14 [10–18] 14 [11–18] 14 [10–18]
Monounsaturated
FA (g/d)
27 [21–35] 26 [20–34] 27 [21–35] 28 [22–35] 28 [22–35] 27 [21–34]
Fruit intake (g/d) 171 [95–281] 87 [44–140] 162 [97–237] 193 [114–300] 224 [139–360] 240 [141–390]
Vegetable intake
(g/d)
161 [105–231] 114 [71–170] 150 [99–211] 168 [114–235] 184 [127–253] 196 [135–272]
Alcohol intake (g/d) 13 [6–31] 11 [3–24] 13 [6–25] 15 [6–34] 14 [7–32] 13 [6–32]
Note: Data expressed asmedian [IQR] unless otherwise stated.
Abbreviations: BMI, bodymass index; CKD, chronic kidney disease; DKK, Danish Krone; FA, fatty acids; HRT, hormone replacement therapy; IQR, interquar-
tile range;MET, metabolic equivalent; NSAID, nonsteroidal anti-inflammatory drug.
demographic and lifestyle factors (Model 1b), participants in quin-
tiles (Q) 2 and 3 had a 24% (HR [95% CI]: 0.76 [0.62, 0.93]) and 30%
(0.70 [0.54, 0.91]) lower risk of vascular dementia, respectively, com-
pared to participants in Q1 (Table 4). Although total flavonoid intake
appeared to be non-linearly inversely associated with AD, this did not
reach statistical significance at any level of flavonoid intake (Figure 1).
Total flavonoid intake did not appear to be associated with unspecified
dementia (Figure 1).
3.3 Associations between flavonoid subclass
intakes and incident dementia
Associations between intakes of flavonols, flavanol oligo + poly-
mers, anthocyanins, flavanones, and flavones and incident demen-
tia were non-linear (Table 3 and Figure 2). For the aforementioned
subclasses, the lowest risks seen for moderate intakes (Q3 and
Q4). No evidence of an association between the flavanol monomers
and incident dementia was observed. Similar associations were also
observed after further adjustments for potential dietary confounders
(Model 2).
3.4 Associations between major flavonoid
compound intakes and incident dementia
Associations between intakes of flavonoid compounds and incident
dementia were assessed only for the subclasses significantly asso-
ciated with a lower risk of dementia in at least one intake quintile
(flavonols, flavanol oligo + polymers, anthocyanins, flavanones, and
flavones). Intakes of quercetin, procyanidin trimers, hesperidin, api-
genin, delphinidin, and malvidin were associated with incident demen-
tia (Figure S1). For all aforementioned compounds, the lowest risks
were seen for moderate intakes (participants in Q3 and Q4; Table S1
in supporting information).
3.5 Associations between total flavonoid intakes
and incident dementia stratified by risk factors for
dementia
The association between total flavonoid intake and incident dementia,
stratified by risk factors for dementia, is presented in Figure 3. The
association appeared to differ by smoking and hypercholesterolemia
BONDONNO ET AL. 7 of 16
F IGURE 1 Cubic spline curves depicting the association between
total flavonoid intake and both total dementia incidence (n= 2955)
and the incidence of dementia subtypes; Alzheimer’s disease
(n= 1348), vascular dementia (n= 329), and unspecified dementia
(n= 1338). Hazard ratios are based on Cox proportional hazards
models adjusted for age, sex, bodymass index, smoking status,
physical activity, alcohol intake, education, and socioeconomic status
(income), and are comparing the specific level of flavonoid intake
(horizontal axis) to themedian intake for participants in the lowest
intake quintile (173mg/d).
status in that there was a statistically significant lower risk of inci-
dent dementia at a moderate total flavonoid intake for “ever” smokers
(Q3 vs. Q1 HR [95% CI]: 0.89 [0.80, 0.99]) and those without hyperc-
holesterolemia (Q4 vs. Q1 HR [95% CI]: 0.84 [0.72, 0.96]), but not for
“never” smokers (Q3 vs. Q1: 1.07 [0.87, 1.31], or those with hyperc-
holesterolemia (Q4 vs. Q1 HR [95% CI]: 1.00 [0.87, 1.14]), after mul-
tivariable adjustments (Model 1b).
3.6 Associations between flavonoid subclass
intakes and vascular dementia
Associations between flavonoid subclasses and vascular dementia
appeared to be non-linear (Table 4 and Figure 4). Intakes of the flavonol
and flavanol oligo + polymer subclasses were associated with incident
vascular dementia, with the lowest risks observed for participants in
Q3. No evidence of an association between the anthocyanin, flavanol
monomer, flavanone, or flavone subclasses and incident dementia was
observed.
3.7 Associations between total flavonoid intakes
and vascular dementia stratified by risk factors for
dementia
The association between total flavonoid intake and vascular demen-
tia, stratified by risk factors for dementia, is presented in Figure 5.
The association appeared to differ by smoking status, alcohol intake,
BMI, and hypocholesteremia; there was a statistically significant lower
risk of vascular dementia with a moderate total flavonoid intake for
“ever” smokers (Q3 vs. Q1 HR [95% CI]: 0.70 [0.53, 0.91]) and those
who were “normal” to “overweight” (Q3 vs. Q1: 0.64 [0.48, 0.85], but
not for “never” smokers [Q3 vs. Q1: 0.95 [0.48, 1.89]) or those who
were “obese” (Q3 vs. Q1: 1.14 [0.60, 2.18]), after multivariable adjust-
ments (Model 1b). Furthermore, the association appeared to be “U-
shaped” in high alcohol consumers and participants who were not
hypercholesteremic. We did not stratify by baseline diabetes status
as there were very few cases of vascular dementia in this subgroup
(n= 18).
3.8 Sensitivity analysis
Defining incident dementia using only dementia-related health-care
visits (n = 2413) the observed association with total flavonoid intakes
was stronger (Figure S3 in supporting information); compared to those
in Q1, the risk of incident dementia was statistically significantly
lower for participants in Q2–4 (HR [95% CIs] for Q2: 0.91 [0.84,
0.99]; Q3: 0.86 [0.77, 0.96]; Q4: 0.86 [0.77, 0.96]; Q5: 0.89 [0.79,
1.01])
4 DISCUSSION
Primary prevention of dementia through modification of lifestyle-
related factors, such as diet, is now recognized to be of importance.3
There is the potential to lower the risk of developing dementia with
evidence-based dietary guidelines focusing on specific dietary compo-
nents, especially in high-risk populations. In this prospective cohort
studyof 55,985Danishmenandwomen,moderate intakes of flavonols,
flavanol oligo+ polymers, anthocyanins, flavanones, and flavoneswere
associated with a lower risk of incident dementia. Additionally, we
observed that moderate intakes of flavonols and flavanol oligo + poly-
mers were significantly associated with a 24% to 30% lower risk of
vascular dementia. The association between total flavonoid intake and
incident dementia appeared to differ by smoking and hypercholes-
terolemia status while the association between total flavonoid intake
and vascular dementia appeared to differ by smoking status, alcohol
intake, BMI, and hypocholesteremia.
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TABLE 3 Hazard ratios of incident dementia by quintiles of flavonoid intake
Flavonoid intake quintiles
Q1 (n= 11,197) Q2 (n= 11,197) Q3 (n= 11,197) Q4 (n= 11,197) Q5 (n= 11,197)
Total flavonoids
No. events 602 595 604 577 577
Intake (mg/d)a 173 (6–251) 320 (251–394) 495 (394–601) 726 (601–908) 1201 (908–3552)
HR (95%CI)
Model 1a ref. 0.94 (0.87, 1.01) 0.88 (0.8, 0.97) 0.85 (0.77, 0.93) 0.87 (0.79, 0.96)
Model 1b ref. 0.96 (0.89, 1.04) 0.93 (0.84, 1.02) 0.91 (0.82, 1.00) 0.95 (0.85, 1.05)
Model 2 ref. 0.95 (0.88, 1.02) 0.91 (0.82, 1.01) 0.89 (0.80, 0.98) 0.93 (0.83, 1.04)
Flavonols
No. events 639 597 559 606 554
Intake (mg/d)a 15 (0–20) 26 (20–32) 38 (32–50) 66 (50–82) 116 (83–251)
HR (95%CI)
Model 1a ref. 0.91 (0.85, 0.97) 0.86 (0.79, 0.94) 0.85 (0.78, 0.94) 0.86 (0.78, 0.95)
Model 1b ref. 0.93 (0.88, 1.00) 0.90 (0.82, 0.99) 0.92 (0.83, 1.01) 0.94 (0.85, 1.04)
Model 2 ref. 0.91 (0.85, 0.98) 0.87 (0.79, 0.96) 0.89 (0.80, 0.98) 0.92 (0.82, 1.02)
Flavanol monomers
No. events 613 572 594 623 553
Intake (mg/d)a 14 (0–21) 30 (21–45) 66 (45–115) 260 (115–281) 473 (281–916)
HR (95%CI)
Model 1a ref. 0.97 (0.93, 1.01) 0.92 (0.83, 1.02) 0.89 (0.81, 0.98) 0.89 (0.81, 0.98)
Model 1b ref. 0.98 (0.94, 1.03) 0.96 (0.87, 1.06) 0.96 (0.87, 1.06) 0.97 (0.88, 1.07)
Model 2 ref. 0.98 (0.94, 1.02) 0.95 (0.85, 1.05) 0.96 (0.87, 1.06) 0.97 (0.88, 1.08)
Flavanol oligo+ polymers
No. events 595 644 556 594 566
Intake (mg/d)a 91 (0–136) 178 (136–217) 255 (217–302) 359 (302–434) 536 (434–2254)
HR (95%CI)
Model 1a ref. 0.92 (0.85, 1.00) 0.86 (0.79, 0.94) 0.81 (0.74, 0.89) 0.83 (0.75, 0.91)
Model 1b ref. 0.95 (0.88, 1.03) 0.91 (0.83, 1.00) 0.87 (0.79, 0.96) 0.89 (0.80, 0.99)
Model 2 ref. 0.94 (0.87, 1.02) 0.89 (0.81, 0.98) 0.85 (0.76, 0.94) 0.87 (0.77, 0.97)
Anthocyanins
No. events 640 589 504 577 645
Intake (mg/d)a 5 (0–10) 13 (10–17) 20 (17–24) 36 (24–53) 71 (53–397)
HR (95%CI)
Model 1a ref. 0.83 (0.77, 0.90) 0.79 (0.72, 0.88) 0.86 (0.78, 0.95) 0.99 (0.9, 1.10)
Model 1b ref. 0.87 (0.80, 0.94) 0.84 (0.76, 0.93) 0.91 (0.82, 1.00) 1.03 (0.92, 1.15)
Model 2 ref. 0.86 (0.79, 0.93) 0.83 (0.75, 0.92) 0.90 (0.81, 0.99) 1.01 (0.90, 1.13)
Flavanones
No. events 658 541 551 573 632
Intake (mg/d)a 3 (0–6) 9 (6–13) 17 (13–26) 32 (26–49) 70 (49–564)
HR (95%CI)
Model 1a ref. 0.91 (0.85, 0.97) 0.86 (0.77, 0.95) 0.89 (0.81, 0.98) 0.98 (0.89, 1.08)
Model 1b ref. 0.93 (0.87, 0.99) 0.89 (0.80, 0.99) 0.93 (0.84, 1.02) 1.01 (0.92, 1.12)
Model 2 ref. 0.92 (0.86, 0.98) 0.87 (0.78, 0.98) 0.91 (0.83, 1.01) 0.99 (0.89, 1.10)
(Continues)
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TABLE 3 (Continued)
Flavonoid intake quintiles
Q1 (n= 11,197) Q2 (n= 11,197) Q3 (n= 11,197) Q4 (n= 11,197) Q5 (n= 11,197)
Flavones
No. events 619 552 559 587 638
Intake (mg/d)a 2 (0–3) 4 (3–4) 5 (4–6) 7 (6–9) 11 (9–51)
HR (95%CI)
Model 1a ref. 0.84 (0.77, 0.92) 0.82 (0.74, 0.90) 0.84 (0.76, 0.92) 0.91 (0.82, 1.00)
Model 1b ref. 0.87 (0.79, 0.95) 0.85 (0.77, 0.95) 0.88 (0.80, 0.97) 0.95 (0.86, 1.05)
Model 2 ref. 0.86 (0.78, 0.94) 0.84 (0.75, 0.93) 0.86 (0.78, 0.95) 0.92 (0.82, 1.03)
Notes: Hazard ratios (95% CI) for incident dementia during 23 years of follow-up, obtained from restricted cubic splines based on Cox proportional hazards
models. Model 1a adjusted for age and sex; Model 1b adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, education, and socioeco-
nomic status (income); Model 2 adjusted for all covariates in model 1b plus energy, intakes of fish, red meat, processed food, polyunsaturated fatty acids,
monounsaturated fatty acids, and saturated fatty acids.
aMedian; range in parentheses (all such values).
Abbreviations: BMI, bodymass index; CI, confidence interval; HR, hazard ratio.
TABLE 4 Hazard ratios of vascular dementia by quintiles of flavonoid intake
Flavonoid intake quintiles
Q1 (n= 11,197) Q2 (n= 11,197) Q3 (n= 11,197) Q4 (n= 11,197) Q5 (n= 11,197)
Total flavonoids
No. events 85 63 61 57 63
Intake (mg/d)a 173 (6–251) 320 (251–394) 495 (394–601) 726 (601–908) 1201 (908–3552)
HR (95%CI)
Model 1a ref. 0.70 (0.57, 0.86) 0.61 (0.47, 0.78) 0.66 (0.51, 0.86) 0.74 (0.55, 0.98)
Model 1b ref. 0.76 (0.62, 0.93) 0.70 (0.54, 0.91) 0.78 (0.59, 1.03) 0.88 (0.65, 1.19)
Model 2 ref. 0.75 (0.61, 0.92) 0.68 (0.52, 0.89) 0.76 (0.56, 1.01) 0.85 (0.62, 1.18)
Flavonols
No. events 88 72 49 54 66
Intake (mg/d)a 15 (0–20) 26 (20–32) 38 (32–50) 66 (50–82) 116 (83–251)
HR (95%CI)
Model 1a ref. 0.71 (0.59, 0.85) 0.60 (0.47, 0.78) 0.70 (0.54, 0.91) 0.75 (0.56, 1.00)
Model 1b ref. 0.76 (0.64, 0.92) 0.69 (0.53, 0.89) 0.83 (0.63, 1.10) 0.91 (0.67, 1.23)
Model 2 ref. 0.73 (0.60, 0.88) 0.64 (0.48, 0.84) 0.79 (0.59, 1.05) 0.86 (0.63, 1.19)
Flavanol monomers
No. events 81 67 64 56 61
Intake (mg/d)a 14 (0–21) 30 (21–45) 66 (45–115) 260 (115–281) 473 (281–916)
HR (95%CI)
Model 1a ref. 0.84 (0.74, 0.96) 0.67 (0.50, 0.90) 0.75 (0.57, 0.99) 0.78 (0.58, 1.03)
Model 1b ref. 0.88 (0.77, 1.00) 0.75 (0.55, 1.01) 0.89 (0.67, 1.20) 0.93 (0.69, 1.26)
Model 2 ref. 0.87 (0.77, 1.00) 0.73 (0.54, 1.00) 0.90 (0.66, 1.21) 0.94 (0.69, 1.27)
Flavanol oligo+polymers
No. events 90 64 53 62 60
Intake (mg/d)a 91 (0–136) 178 (136–217) 255 (217–302) 359 (302–434) 536 (434–2254)
HR (95%CI)
Model 1a ref. 0.63 (0.51, 0.78) 0.57 (0.45, 0.72) 0.63 (0.49, 0.82) 0.69 (0.52, 0.91)
Model 1b ref. 0.70 (0.57, 0.86) 0.65 (0.51, 0.83) 0.74 (0.56, 0.97) 0.81 (0.60, 1.09)
Model 2 ref. 0.68 (0.55, 0.85) 0.63 (0.49, 0.82) 0.71 (0.53, 0.94) 0.77 (0.56, 1.06)
(Continues)
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TABLE 4 (Continued)
Flavonoid intake quintiles
Q1 (n= 11,197) Q2 (n= 11,197) Q3 (n= 11,197) Q4 (n= 11,197) Q5 (n= 11,197)
Anthocyanins
No. events 71 69 49 62 78
Intake (mg/d)a 5 (0–10) 13 (10–17) 20 (17–24) 36 (24–53) 71 (53–397)
HR (95%CI)
Model 1a ref. 0.80 (0.63, 1.02) 0.74 (0.55, 1.01) 0.79 (0.60, 1.04) 0.98 (0.72, 1.32)
Model 1b ref. 0.90 (0.71, 1.15) 0.88 (0.65, 1.19) 0.91 (0.68, 1.22) 1.08 (0.79, 1.50)
Model 2 ref. 0.90 (0.71, 1.15) 0.88 (0.64, 1.19) 0.92 (0.68, 1.23) 1.08 (0.78, 1.50)
Flavanones
No. events 85 51 67 62 64
Intake (mg/d)a 3 (0–6) 9 (6–13) 17 (13–26) 32 (26–49) 70 (49–564)
HR (95%CI)
Model 1a ref. 0.86 (0.70, 1.05) 0.78 (0.57, 1.06) 0.81 (0.61, 1.07) 0.88 (0.66, 1.18)
Model 1b ref. 0.91 (0.75, 1.11) 0.87 (0.63, 1.19) 0.91 (0.69, 1.21) 0.97 (0.73, 1.31)
Model 2 ref. 0.91 (0.74, 1.11) 0.86 (0.62, 1.18) 0.90 (0.68, 1.20) 0.96 (0.71, 1.29)
Flavones
No. events 68 61 65 61 74
Intake (mg/d)a 2 (0–3) 4 (3–4) 5 (4–6) 7 (6–9) 11 (9–51)
HR (95%CI)
Model 1a ref. 0.87 (0.66, 1.14) 0.84 (0.62, 1.14) 0.84 (0.63, 1.12) 0.92 (0.68, 1.25)
Model 1b ref. 0.97 (0.73, 1.27) 0.96 (0.71, 1.30) 0.98 (0.73, 1.30) 1.05 (0.78, 1.44)
Model 2 ref. 0.98 (0.74, 1.29) 0.98 (0.74, 1.29) 1.00 (0.74, 1.36) 1.09 (0.77, 1.52)
Notes: Hazard ratios (95% CI) for vascular dementia during 23 years of follow-up, obtained from restricted cubic splines based on Cox proportional hazards
models. Model 1a adjusted for age and sex; Model 1b adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, education, and socioeco-
nomic status (income); Model 2 adjusted for all covariates in model 1b plus energy, intakes of fish, red meat, processed food, polyunsaturated fatty acids,
monounsaturated fatty acids, and saturated fatty acids.
aMedian; range in parentheses (all such values).
Abbreviations: BMI, bodymass index; CI, confidence interval; HR, hazard ratio.
While there is a growing body of evidence that particular dietary
patterns, such as the Mediterranean diet, are associated with a lower
risk of dementia30 and reduced dementia-related neuropathology,31
to our knowledge few prospective studies to date have investigated
flavonoid intake and dementia. In the Paquid study, flavonoid intake
(mean, 14.4 mg/d) was associated with a 51% (relative risk: 0.49, 95%
CI: 0.26, 0.92) lower risk of dementia (66 incident cases) in 1367 sub-
jects over theageof65and followedup for5years.14 Lefèvre-Arbogast
et al. identified a pattern of polyphenol intake (mean, 1071 mg/d)
associated with a 50% (HR: 0.50, 95% CI: 0.32, 0.80) lower risk of
dementia (256 incident cases) in 1329 older adults followed for 12
years in the Three-City Study.17 Conversely, flavonoid intake at base-
line (mean, 28.5 mg/d) was not associated with dementia (465 incident
cases) in 5395 participants of the Rotterdam Study after a mean of 9.6
years follow-up.15 Flavonoid intake (estimated using a mean intake of
tea as a proxy, 2 to 6 mg/d), was not associated with dementia (235
incident cases) after 30 years of follow-up in 2459 men and women
enrolled in the Honolulu-Asia Aging Study.16 More recently, partici-
pants of the FraminghamHeart Study offspring cohort (2801 followed
for 19.7 years, 193 incident cases of dementia), individuals with the
highest flavonol, anthocyanins, and flavonoid polymers intake (based
on a cumulative average across five exams) had a 46%, 76%, and 42%
lower risk of dementia, respectively, compared to participants with the
lowest intakes.32 Evidence from observational studies investigating
flavonoid-rich foods and risk of dementia indicate potential protective
effects for vegetables, particularly green leafy vegetables; fruit, partic-
ularly berries; and coffee and tea.33 The present study is the largest
study to date investigating flavonoid intake and risk of dementia (2955
incident cases diagnosed during follow-up). It is, however, difficult to
compare results between our study and previous studies due to incon-
sistencies in the number of different flavonoid subclasses considered
and methods of calculation. For reference, median and mean flavonoid
intakes in the present study were 494 and 596 mg/d, respectively, cal-
culated using estimates of 219 compounds. Our results are consis-
tent with recent flavonoid intake calculations using the United States
Department of Agriculture and Phenol-Explorer databases.24,34,35
Of dementia subtypes, a statistically significant association was
only observed between total flavonoid intake and vascular dementia.
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F IGURE 2 Hazard ratios based on cubic spline curves to depict the association between flavonoid subclass intakes (mg/d) and all cases of
incident dementia among participants of the Danish Diet, Cancer, and Health cohort. Hazard ratios are based on Cox proportional hazardsmodels
adjusted for age, sex, bodymass index, smoking status, physical activity, alcohol intake, education, and socioeconomic status (income), and are
comparing the specific level of flavonoid intake (horizontal axis) to themedian intake for participants in the lowest intake quintile
Compared to those with low flavonoid intakes, a 24% to 30% lower
risk of vascular dementia was observed for participants withmoderate
flavonoid intakes. Vascular dementia can be a consequence of stroke
and microvascular disease, and is estimated to account for 15% to
20% of all dementia cases.36 It is important to note, however, that AD
(the most common form of dementia) and vascular dementia are not
distinct, and there is an overlap in underlying pathology; cerebrovas-
cular dysfunction is prominent in AD37 and pure vascular dementia
(dementia caused solely by vascular pathology) is relatively rare.38
There is a growing bodyof evidence supporting the beneficial effects of
flavonoids on cardiovascular health and by extension, cerebrovascular
health.9,39 While a wide range of potential biological mechanisms have
been reported for flavonoids and flavonoid-rich foods,40 benefits of
specific flavonoid subclasses on vascular health could be mediated by
enhanced nitric oxide bioavailability,9 increased expression of heme-
oxygenase-1,41 inhibition of angiotensin-converting enzyme activity,42
effects on cholesterol,43 and improved inflammatory status,44 or a
complexmilieu of all these beneficial effects.
Interestingly, while no association was observed between total
flavonoid intake and incident dementia, a non-linear inverse
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F IGURE 3 Multivariable-adjusted association between total flavonoid intake and incident dementia stratified by baseline smoking status,
alcohol intake, bodymass index (BMI), sex, diabetes status, cholesterol levels, and hypertension status. Hazard ratios are based on Cox
proportional hazards models and are comparing the specific level of flavonoid intake (horizontal axis) to themedian intake for participants in the
lowest intake quintile (173mg/d). All analyses were standardized for age, sex, BMI, smoking, physical activity, alcohol intake, education, and
socioeconomic status (income)
association was observed for specific flavonoid subclasses and
some of their individual flavonoid compounds. This is not surprising
given the structural variations between the flavonoid subclasses, and
their respective major compounds, which influences bioavailability
and biological activity.18 Evidence for a threshold after which higher
flavonoid intakes afford no added benefit, is not newand has been seen
for other outcomes in the same cohort.7,19 Furthermore, our study
suggests a U-shaped association between intakes of several flavonoid
subclasses and incident dementia. We hypothesize that this is driven
by the co-occurrence of other, potentially detrimental, dietary factors
(e.g., added sugar in anthocyanin-rich fruit juice/squash) in flavonoid-
rich foods. A lower risk of dementia was observed at moderate intakes
of the flavonols, flavanol oligo + polymers, anthocyanins, flavanones.
and flavones subclasses. These findings support a growing body of
evidence in the literature that flavonols, flavanols, anthocyanins,
and flavanones are the most neuro-protective of all the flavonoids
subclasses, improving measures of cognitive function and limiting cog-
nitive decline.45–53 A moderate intake of these flavonoid subclasses is
well within achievable daily dietary limits: one cup of tea, one apple,
one orange, 50 g of blueberries, and 50 g of dark chocolate would
provide these flavonoid subclasses and more than 500 mg of total
flavonoids.
The association between total flavonoid intake and both inci-
dent and vascular dementia was only present in current and for-
mer smokers; there was no association in participants who had
never smoked. Smoking is strongly associated with a higher risk of
dementia.54 A recent meta-analysis of 37 studies observed a 30%
higher risk of all-cause dementia (relative risk: 1.30, 95% CI: 0.18,
0.45) for participants who currently smoke compared to those who
have never smoked.54 It is proposed that smoking increases the risk of
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F IGURE 4 Hazard ratios based on cubic spline curves to depict the association between flavonoid subclass intakes (mg/d) and all cases of
vascular dementia among participants of the Danish Diet, Cancer, and Health cohort. Hazard ratios are based on Cox proportional hazards models
adjusted for age, sex, bodymass index, smoking status, physical activity, alcohol intake, education, and socioeconomic status (income), and are
comparing the specific level of flavonoid intake (horizontal axis) to themedian intake for participants in the lowest intake quintile
vascular dementia via detrimental effects on cerebrovascular health.55
In the current study, the inverse association of total flavonoid intake
with incident dementia observed in participants who smoked or had
ever smoked is likely related to the protective effect of flavonoids on
vascular health. Of note, a randomized controlled trial conducted in
healthy individuals who smoked observed that flavonoid-rich grape
juice intake restored vascular function.56 That the associationbetween
total flavonoid intake andvascular dementiawasonly present in partic-
ipants who were “normal” to “overweight” at baseline could be related
to differences in gut microbiome composition,57 which plays a cru-
cial role in flavonoid metabolism.58 However, as the number of partic-
ipants who were “obese” was low and associated confidence intervals
are wide, this requires further investigation. Furthermore, the pres-
ence of an association between total flavonoid intake and vascular
dementia, but not incident dementia, in participants whowere hyperc-
holesteremic at baseline requires further investigation taking into con-
sideration treatment or changes in hypercholesteremia status during
follow-up. Given the low number of vascular dementia cases in this
cohort, and that associations were stratified over several effect mod-
ifiers thereby increasing the likelihood of spurious associations, these
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F IGURE 5 Multivariable-adjusted association between total flavonoid intake and vascular dementia stratified by baseline smoking status,
alcohol intake, bodymass index (BMI), sex, diabetes status, hypertension status, and cholesterol levels. Hazard ratios are based on Cox
proportional hazards models and are comparing the specific level of flavonoid intake (horizontal axis) to themedian intake for participants in the
lowest intake quintile (173mg/d). All analyses were standardized for age, sex, BMI, smoking, physical activity, alcohol intake, education, and
socioeconomic status (income)
stratified analyses should be interpreted with caution and viewed as
exploratory.
Our cohort studyhas anumberof strengths. The23-yeardurationof
follow-upwith very limited loss to follow-up allowed for the accumula-
tion of a large number of incident cases despite the protracted nature
of the disease. The length of follow-up and age of enrolment (∼50
years) also allowed for the examination of flavonoid intake in associa-
tion withmid-life risk factors. This is important as substantial evidence
indicates that mid-life risk factors (hypertension, obesity, cholesterol,
smoking, and physical activity) are important for predicting dementia
risk in later life.4
As this is an observational study a number of limitations apply. We
are unable to infer causality or rule out residual or unmeasured con-
founding factors. Flavonoids could also be a surrogate marker of a
healthier diet and lifestyle. However, the association between a higher
flavonoid intake and a lower risk of vascular dementia was still present
after adjustment for lifestyle factors and other indicators of a healthy
diet. While the 23-year duration of follow-up allowed for the long pre-
clinical phase of dementia to be considered, dietary intake data was
only captured at baseline anddietary habitsmayhave changedover the
23 years of follow-up. Any such changes, however, would likely have
attenuated the observed association. Due to the number of flavonoid
subclasses and their individual flavonoid compounds making up the
subclasses, a number of statistical tests were performed. However,
these testswere hypothesis driven given the current knowledge on the
bioavailability, bioefficacy, and mechanistic understanding of the dif-
ferent subclasses. Additionally, other than a dementia diagnosis (study
exclusion criteria), there was no information on cognitive impairment
at baseline, nor detailed information at follow-up (beyond a diagnosis
of dementia in the DNPR or prescription for an anti-dementia drug in
theDNPR). Additionally, dementia incidencemay have been underesti-
mated as participantswho did not takemedication for the treatment of
dementia andwhodidnothaveahealth-care visitwith adementia diag-
nosis code would have been missed. Further, no studies are available
providing PPVs for dementia diagnoses defined as either a dementia-
related health-care visit or a prescription for an anti-dementia drug.
However, the association between total flavonoid intake and incident
dementia was stronger in a sensitivity analysis using only dementia-
related health-care visits as the outcome, which has a PPV of 85.8%
in the DNPR.27 This may be because the inclusion of a redeemed
prescription for an anti-dementia drug in the outcome may decrease
specificity, particularly if such drugs are used off-label in Denmark.
Dementia can only be definitively diagnosed post mortem, although
brain imaging increases diagnostic accuracy significantly. This raises
the issue of individuals being incorrectly classified (particularly with
respect to dementia subtypes). The ICD-10 registration of subtypes of
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dementia is underreported in the DNPR and thus subtype analysis
should be interpreted with caution.26 Finally, the participants in this
study were most likely White, meaning that caution should be taken
when extrapolating these findings to other ethnicities. Further studies
in other populations are required to confirm our findings.
In conclusion, in this large prospective cohort study of Danish men
andwomenweobserved that amoderate and achievable dietary intake
of total flavonoids was associated with significantly lower risk of vas-
cular dementia. Specific subclasses, flavanol oligo + polymers and
flavonols, were associated with a lower risk of both incident and vas-
cular dementia. Our results suggest that small changes to the habit-
ual diet, encouraging consumption of flavonoid-rich foods among low-
flavonoid consumers may help to lower the risk of dementia.
ACKNOWLEDGMENTS
The Danish Diet, Cancer, and Health Study was funded by the Dan-
ish Cancer Society, Denmark. FD is funded by The Danish Heart Foun-
dation (Grant number 17-R115-A7443-22062) and Gangstedfonden
(Grant numberA35136), Denmark. NPB is funded by aNational Health
andMedical Research Council Early Career Fellowship (Grant number
APP1159914), Australia. The salary of JRL is supported by a National
Heart Foundation of Australia Future Leader Fellowship (ID: 102817).
The salary of JMH is supported by a National Health and Medical
Research Council of Australia Senior Research Fellowship, Australia
(Grant number APP1116937). SRRS is supported by a BrightFocus
Foundation Fellowship, USA.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
DISCLAIMER
Where authors are identified as personnel of the International Agency
for Research on Cancer/World Health Organization, the authors alone
are responsible for the views expressed in this article and they do not
necessarily represent the decisions, policy, or views of the Interna-
tional Agency for Research on Cancer/World Health Organization.
REFERENCES
1. PattersonC.World Alzheimer report 2018: the state of the art of dementia
research: new frontiers. London, UK: Alzheimer’s Disease International
(ADI); 2018.
2. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention,
intervention, and care: 2020 report of the Lancet Commission. Lancet.
2020;396:413-446.
3. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention,
intervention, and care. Lancet. 2017;390:2673-2734.
4. Bendlin B, Carlsson C, Gleason C, et al. Midlife predictors of
Alzheimer’s disease.Maturitas. 2010;65:131-137.
5. Larson EB, Yaffe K, Langa KM. New insights into the dementia epi-
demic.N Engl J Med. 2013;369:2275-2277.
6. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s dis-
ease and other dementias: a priority for European science and society.
Lancet Neurol. 2016;15:455-532.
7. BondonnoNP, Dalgaard F, Kyrø C, et al. Flavonoid intake is associated
with lowermortality in theDanishDiet Cancer andHealthCohort.Nat
Commun. 2019;10:1-10.
8. HertogMG, Kromhout D, Aravanis C, et al. Flavonoid intake and long-
term risk of coronary heart disease and cancer in the seven countries
study. Arch InternMed. 1995;155:381-386.
9. Bondonno CP, Croft KD,Ward N, ConsidineMJ, Hodgson JM. Dietary
flavonoids and nitrate: effects on nitric oxide and vascular function.
Nutr Rev. 2015;73:216-235.
10. Spencer JP. The impact of fruit flavonoids onmemory and cognition.Br
J Nutr. 2010;104:S40-S7.
11. Caldwell K, Roodenrys S, Charlton K, Richards R, Morgan O. Dietary
flavonoid intake and cognitive performance in older adults with
Alzheimer’s type dementia. J Aging Res Clin Pract. 2016;5:93-97.
12. Devore EE, Kang JH, Breteler MM, Grodstein F. Dietary intakes of
berries and flavonoids in relation to cognitive decline. Ann Neurol.
2012;72:135-143.
13. Letenneur L, Proust-Lima C, Le Gouge A, Dartigues J-F, Barberger-
GateauP. Flavonoid intakeandcognitivedeclineover a10-yearperiod.
Am J Epidemiol. 2007;165:1364-1371.
14. Commenges D, Scotet V, Renaud S, Jacqmin-Gadda H, Barberger-
Gateau P, Dartigues J-F. Intake of flavonoids and risk of dementia. Eur
J Epidemiol. 2000;16:357-363.
15. Devore EE, Grodstein F, van Rooij FJ, et al. Dietary antioxidants and
long-term risk of dementia. Arch Neurol. 2010;67:819-825.
16. Laurin D, Masaki KH, Foley DJ, White LR, Launer LJ. Midlife dietary
intake of antioxidants and risk of late-life incident dementia: the
Honolulu-Asia Aging Study. Am J Epidemiol. 2004;159:959-967.
17. Lefèvre-Arbogast S, Gaudout D, Bensalem J, et al. Pattern of polyphe-
nol intake and the long-term risk of dementia in older persons.Neurol-
ogy. 2018;90:e1979-e88.
18. Rodriguez-Mateos A, Vauzour D, Krueger CG, et al. Bioavailability,
bioactivity and impact on health of dietary flavonoids and related com-
pounds: an update. Arch Toxicol. 2014;88:1803-1853.
19. Dalgaard F, Bondonno NP, Murray K, et al. Associations between
habitual flavonoid intake and hospital admissions for atheroscle-
rotic cardiovascular disease: a prospective cohort study. Lancet Planet
Health. 2019;3:e450-e9.
20. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L,
Sørensen HT. The Danish National Patient Registry: a review of con-
tent, data quality, and research potential. Clin epidemiol. 2015;7:449.
21. LyngeE, Sandegaard JL, ReboljM. TheDanishnational patient register.
Scand J Public Health. 2011;39:30-33.
22. Wallach Kildemoes H, Toft Sørensen H, Hallas J. The Danish national
prescription registry. Scand J Public Health. 2011;39:38-41.
23. Neveu V, Perez-Jiménez J, Vos F, et al. Phenol-Explorer: an online
comprehensive database on polyphenol contents in foods. Database.
2010;2010.
24. Perez-Jimenez J, Fezeu L, Touvier M, et al. Dietary intake of 337
polyphenols in French adults. Am J Clin Nutr. 2011;93:1220-1228.
25. Fann JR, Ribe AR, Pedersen HS, et al. Long-term risk of dementia
among people with traumatic brain injury in Denmark: a population-
based observational cohort study. Lancet Psychiatry. 2018;5:424-431.
26. Phung TKT,Waltoft BL, Kessing LV,Mortensen PB,Waldemar G. Time
trend in diagnosing dementia in secondary care. Dement Geriatr Cogn
Disord. 2010;29:146-153.
27. Phung TKT, Andersen BB, Høgh P, Kessing LV, Mortensen PB, Walde-
mar G. Validity of dementia diagnoses in the Danish hospital registers.
Dement Geriatr Cogn Disord. 2007;24:220-228.
28. Noordzij M, Leffondré K, van Stralen KJ, Zoccali C, Dekker FW, Jager
KJ.When do we need competing risks methods for survival analysis in
nephrology?Nephrol Dial Transplant. 2013;28:2670-2677.
29. R Development Core Team. R: A language and environment for statisti-
cal computing. Vienna, Austria: R Foundation for Statistical Computing
ISBN 3-900051-07-0. URL: http://www.R-project.org/; 2019.
30. van de Rest O, Berendsen AA, Haveman-Nies A, de Groot LC. Dietary
patterns, cognitive decline, and dementia: a systematic review. Adv
Nutr. 2015;6:154-168.
16 of 16 BONDONNO ET AL.
31. Rainey-Smith SR, Gu Y, Gardener SL, et al. Mediterranean diet adher-
ence and rate of cerebral Aβ-amyloid accumulation: data from theAus-
tralian imaging, biomarkers and lifestyle study of ageing. Transl Psychi-
atry. 2018;8:1-7.
32. Shishtar E, Rogers GT, Blumberg JB, Au R, Jacques PF. Long-term
dietary flavonoid intake and risk of Alzheimer disease and related
dementias in the Framingham Offspring Cohort. Am J Clin Nutr.
2020;112:343-353.
33. Scarmeas N, Anastasiou CA, Yannakoulia M. Nutrition and prevention
of cognitive impairment. Lancet Neurol. 2018;17:1006-1015.
34. Cassidy A, Rimm EB, O’Reilly ÉJ, et al. Dietary flavonoids and risk of
stroke in women. Stroke. 2012;43:946-951.
35. Ivey KL, Hodgson JM, Croft KD, Lewis JR, Prince RL. Flavonoid intake
and all-causemortality. Am J Clin Nutr. 2015;101:1012-1020.
36. Wolters FJ, Ikram MA. Epidemiology of vascular dementia. Arter
Thromb Vasc Biol. 2019;39:1542-1549.
37. Sweeney MD, Montagne A, Sagare AP, et al. Vascular dysfunction-
the disregarded partner of Alzheimer’s disease. Alzheimers Dement.
2019;15:158-167.
38. van der Flier WM, Skoog I, Schneider JA, et al. Vascular cognitive
impairment.Nat Rev Dis Primers. 2018;4:18003.
39. Hooper L, Kroon PA, Rimm EB, Cohn JS, et al. Flavonoids, flavonoid-
rich foods, and cardiovascular risk: ameta-analysis of randomized con-
trolled trials. Am J Clin Nutr. 2008;88:38-50.
40. Williamson G, Kay CD, Crozier A. The bioavailability, transport, and
bioactivity of dietary flavonoids: a review fromahistorical perspective.
Compr Rev Food Sci Food Saf. 2018;17:1054-1112.
41. Croft KD, Zhang D, Jiang R, et al. Structural requirements of
flavonoids to induce heme oxygenase-1 expression. Free Rad Biol Med.
2017;113:165-175.
42. Guerrero L, Castillo J, Quiñones M, et al. Inhibition of angiotensin-
converting enzyme activity by flavonoids: structure-activity relation-
ship studies. PloS one. 2012;7.
43. Raman G, Avendano EE, Chen S, et al. Dietary intakes of flavan-3-
ols and cardiometabolic health: systematic review and meta-analysis
of randomized trials and prospective cohort studies. Am J Clin Nutr.
2019;110:1067-1078.
44. García-Lafuente A, Guillamón E, Villares A, Rostagno MA, Martínez
JA. Flavonoids as anti-inflammatory agents: implications in cancer and
cardiovascular disease. InflammRes. 2009;58:537-552.
45. Bergland AK, Soennesyn H, Dalen I, et al. Effects of anthocyanin sup-
plementation on serum lipids, glucose, markers of inflammation and
cognition in adults with increased risk of dementia–a pilot study. Front
Genet. 2019;10:536.
46. BrickmanAM,KhanUA,ProvenzanoFA, et al. Enhancingdentate gyrus
function with dietary flavanols improves cognition in older adults.Nat
Neurosci. 2014;17:1798.
47. Dodd GF, Williams CM, Butler LT, Spencer JP. Acute effects of
flavonoid-rich blueberry on cognitive and vascular function in healthy
older adults.Nutr Health Aging. 2019:1-14.
48. Kent K, Charlton K, Roodenrys S, et al. Consumption of anthocyanin-
rich cherry juice for 12weeks improvesmemory and cognition in older
adults withmild-to-moderate dementia. Eur J Nutr. 2017;56:333-341.
49. Mastroiacovo D, Kwik-Uribe C, Grassi D, et al. Cocoa flavanol con-
sumption improves cognitive function, blood pressure control, and
metabolic profile in elderly subjects: the Cocoa, Cognition, and
Aging (CoCoA) Study—a randomized controlled trial. Am J Clin Nutr.
2014;101:538-548.
50. Neshatdoust S, Saunders C, Castle SM, et al. High-flavonoid intake
induces cognitive improvements linked to changes in serum brain-
derived neurotrophic factor: two randomised, controlled trials. Nutr
Healthy Aging. 2016;4:81-93.
51. Watson AW, Haskell-Ramsay CF, Kennedy DO, Cooney JM, Trower
T, Scheepens A. Acute supplementation with blackcurrant extracts
modulates cognitive functioning and inhibits monoamine oxidase-B in
healthy young adults. J Funct Foods. 2015;17:524-539.
52. Willis LM, Shukitt-Hale B, Joseph JA. Recent advances in berry supple-
mentation and age-related cognitive decline.Curr Opin Clin NutrMetab
Care. 2009;12:91-94.
53. Holland TM, Agarwal P, Wang Y, et al. Dietary flavonols and risk of
Alzheimer dementia.Neurology. 2020;94:e1749-e56.
54. Zhong G, Wang Y, Zhang Y, Guo JJ, Zhao Y. Smoking is associated
with an increased risk of dementia: a meta-analysis of prospective
cohort studies with investigation of potential effect modifiers. PLOS
ONE. 2015;10:e0118333.
55. Peters R. Blood pressure, smoking and alcohol use, association with
vascular dementia. Exp Gerontol. 2012;47:865-872.
56. Siasos G, Tousoulis D, Kokkou E, et al. Favorable effects of concord
grape juice on endothelial function and arterial stiffness in healthy
smokers. Am J Hypertens. 2013;27:38-45.
57. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J
Clin Invest. 2011;121:2126-2132.
58. Cassidy A, Minihane A-M. The role of metabolism (and the micro-
biome) in defining the clinical efficacy of dietary flavonoids. Am J Clin
Nutr. 2017;105:10-22.
SUPPORTING INFORMATION
Additional supporting informationmay be found online in the Support-
ing Information section at the end of the article.
How to cite this article: Bondonno CP, BondonnoNP,
Dalgaard F, et al. Flavonoid intake and incident dementia in the
Danish Diet, Cancer, and Health cohort. Alzheimer’s Dement.
2021;7:e12175. https://doi.org/10.1002/trc2.12175
